

glands and tumor cells. Negligible androgen levels prevent stimulation of the intracellular receptor in the tumor cell, reducing PSA synthesis and growth factors.

Objectives. To demonstrate the therapeutic benefits and tolerance to abiraterone in elderly patients with metastatic castration-resistant prostate cancer.

Methods. 82 year old man, diagnosed with prostate adenocarcinoma in 2005 (75 year old), PSA 23, Gleason 6, T2b. Received complete androgen deprivation therapy alone (anti-androgen and GnRH agonist), follow-up examination showed PSA 0,04 decline in 2006, then progression to PSA 19,4 and bone scan suggestive of pelvic bone metastasis (2011). Discontinued treatment with anti-androgen. PSA rise to 43.74 in January 2012, 10 mg/24h prednisone prescribed. Follow-up showed PSA rise to 61 and alkaline phosphatase 300 in August 2012. Bone scan suggested metastasis in iliac and sacrum bone. Patient refers mild pain in rest and moderate pain while moving, no other symptoms associated. Karnofsky 95%, the CT extension study showed large bone metastatic spread and no visceral or lymph node involvement. Follow-up showed PSA 140, alkaline phosphatase 501, testosterone level less than 3 ng/dl in October 2012. Abiraterone acetate 1000 mg daily and prednisone 5 mg BID prescribed. Zoledronic acid 4 mg iv/28 days and calcium and vitamin D oral. Pain management with oxycodone–naloxone 20/10/12h and ibuprofen 600 mg/12h.

Results. Follow-up showed decline of PSA 27, alkaline phosphatase 300 and pain control improvement with no effect on blood test results including liver function (normal hepatic enzymes level) in February 2013 (4 months after treatment start).

Conclusions. Abiraterone demonstrates its feasibility as therapeutic choice for elderly patients due to good tolerance.

<http://dx.doi.org/10.1016/j.rpor.2013.03.469>

Acute toxicity after combined HDR-BT and EBRT for prostate cancer

S. Roldán Ortega, O. Pons Llanas, E. Cuervo Madrid, T. García, R. Palomo, F. Martínez Arcelus, F. Celada Álvarez, E. Collado Ballesteros, M. García Mora, A. Tormo Micó, J. Pérez Calatayud
Hospital Universitario la fe, Oncología Radioterápica, Spain



Introduction. Clinical evidences support dose escalation radiotherapy for unfavorable prostate cancer (PCa). To achieve it, we combine Ir-192 High Dose Rate Brachytherapy (HDR-BT) with External Beam Radiotherapy (EBRT).

Purpose. Evaluation of acute urinary and intestinal toxicity during the following 6 months after treatment. Since almost all patients were under androgen deprivation therapy (ATD), sexual toxicity has not been analyzed.

Methods. Between August 2010 and May 2012, 67 patients with intermediate/high risk PCa were treated. Median age: 75 (62–82). Median follow-up: 14 months (6–29). Five patients had previous TURP and 3 had previous adenectomy. EBRT administration was 200 cGy/fraction, 5/week. Median needles used for HDR-BT procedure was 18 (12–27). If seminal vesicles involvement (21 patients), a single fraction of 9–9.5Gy HDR-BT plus 60 Gy EBRT to pelvis and/or prostate-vesicles, was administrated. When seminal vesicles were not infiltrated (46 patients), a single fraction of 15 Gy HDR-BT plus 46 Gy EBRT to pelvis or prostate-vesicles. Sixty-one patients included ATD for 6 months in intermediate (24 patients) and 12–36 months in high risk PCa (37 patients). Toxicity evaluated following RTOG/EORTC criteria.

Results. After one month: 18 patients (26.8%) presented urinary toxicity; 16 G1 cases (dysuria and/or urgency), 1 G2 case (nocturia) and 1 G4 case (complete urinary retention). Three patients presented intestinal G1 toxicity (diarrhea and/or mild bleeding). After three months: 17 patients (25.3%) presented urinary toxicity; 13 G1 cases, 3 G2 cases and only one G4. Four G1 intestinal toxicity cases were observed. After six months: 17 patients (25.3%) presented urinary toxicity; 10 G1 cases, 6 G2 cases, and 1 G4 case. Only one patient presented G1 intestinal toxicity.

Conclusion. We found acceptable acute toxicity results. Main symptoms were dysuria and nocturia, most of them Grade 1. Only three urinary G4 cases observed along the analyzed period. Intestinal toxicity cases were few and mild.

<http://dx.doi.org/10.1016/j.rpor.2013.03.470>

Acute toxicity in hypofractionated radiotherapy for prostate cancer

C. de Haro Bueno¹, J. Reinoso Cobo², M. Martos Alcalde¹, J. García Madueño², J. Richarte Reina², M. Capllonch Blanco¹, M. Casanova García¹, A. Cabrero Chinchilla¹, A. Cid Galache²

¹ Complejo Hospitalario ciudad de Jaén, Radiation Oncology, Spain

² Complejo Hospitalario ciudad de Jaén, Hospitalary Radiophysics Unit, Spain



Introduction. Recent publications have indicated that the α/β ratio for prostate carcinoma is much lower than previously established, suggesting that these tumours are much more sensitive to the dose administered per fraction. We do not know if the hypofractionated treatment provides clinical benefit in the treatment of prostate tumours.

Purpose. Assessment of the acute toxicity in patients diagnosed with prostate carcinoma and treated with hypofractionated radiotherapy.

Methods and material. Between January 2012 and May 2012, 78 men were treated at the Hospitalary Radiophysics Unit of the Hospital Complex of Jaén with ages comprised between 46 and 78 years old (average 68.3 years old), KPS 90–100%. They were diagnosed with prostate adenocarcinoma, PSA between 4 and 188 ngr/ml (average 16.39), Gleason 6 (56.5%) – 7 (23%) – 8 (9%) – 9 (5%) – others (6.5%), clinical stage T1c (65.4%), T2 (19.2%), T3 (15.4%). 78% of the cases were treated with androgen deprivation.